The compliance committee of a pharmaceutical company learns that salespeople in the marketing department have been pushing doctors to prescribe a particular medication for the treatment of heart palpitations, a use not approved by the Food and Drug Administration (FDA). Such conduct would constitute a violation of “off-label” marketing rules under federal law. The practice appears to be widespread and to have been coordinated by the vice president in charge of heart medications. As chair of the committee, you discuss these findings with the chief executive officer, who expresses the concern that if these activities are made public, the company will be sued for millions of dollars. He asks if the matter can be handled internally, without informing the FDA. What should you do?